Carina awarded Department of Industry CRC-P grant
A big day for us here at Carina Biotech. Minister Anne Ruston joined our management team and two researcher leaders Professor Simon Barry and Professor Shaun McColl at University of Adelaide today to
CAR-T therapy clinical trials to start in Australia in 2019
Off-the-shelf CAR-T therapy clinical trials to start in Australia next year CANCER patients would have access to off-the-shelf immunotherapies to reprogram their immune system to fight tumours at a fraction
Carina Receives Major Funding Boost
Carina receives major funding boost to take its CAR-T research to the next stage This week, our CEO Dr Justin Coombs was in Melbourne for the formal presentation to Carina
Adelaide’s Carina Makes Killer Cells to Cure Cancer
Adelaide’s Carina Biotech Makes Killer Cells to Cure Cancer ADELAIDE scientists are leading the charge to cure all kinds of cancer, not just blood cancer, using the body’s own immune
New Frontier in Cancer Care
New frontier in cancer care: Turning blood into living drugs KEN Shefveland’s body was swollen with cancer, treatment after treatment failing until doctors gambled on a radical approach: They removed
Multiple Myeloma Sent into Lasting Remission
CAR T-Cell Therapy Sends Multiple Myeloma Into Lasting Remission ASCO Perspective: “While it’s still early, these data are a strong sign that CAR T-cell therapy can send multiple myeloma into remission,”
Novartis Receives FDA Breakthrough
Novartis CAR-T cell therapy CTL019 receives FDA breakthrough therapy designation for treatment of adult patients with r/r DLBCL Designation prioritises investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients
TeamKids Easter Appeal Raises >$1M
2017 TeamKids Easter appeal raises >$1M TeamKids – Women’s & Children’s Hospital Foundation would like to thank everyone for their kind generosity in supporting the TeamKids Easter Appeal which was held on Good Friday, 14 April
Also in 2017
Also in 2017, the FDA approved for use two CAR-T cell therapies to treat children and young adults with ALL and adults with diffuse large B-cell lymphoma.
In 2017
In 2017 CAR-T therapy was named Advance of the Year by the American Society for Clinical Oncology.